ICIs for Treatment of Melanoma
| ICI | Target | Landmark clinical trials | Typical use settings |
|---|---|---|---|
| Ipilimumab | CTLA-4 | Hodi et al. (49); EORTC 18071 (54) | In combination with other agents as below |
| Nivolumab | PD-1 | CheckMate 066 (79); CheckMate 238 (57) | Adjuvant, in combination with other agents |
| Pembrolizumab | PD-1 | SWOG 1801 (63); KEYNOTE-054 (55) | Neoadjuvant, adjuvant |
| Ipilimumab + nivolumab | PD-1/CTLA-4 | CheckMate 067 (51); NADINA (80) | Neoadjuvant, adjuvant, metastatic |
| Nivolumab + relatlimab | PD-1/LAG-3 | RELATIVITY-047 (53) | Metastatic |